Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Navtemadlin Placebo
DRUG
3 trials
Sponsors
Kartos Therapeutics, Inc.
Conditions
Endometrial Cancer
MF
Myelofibrosis
Non Small Cell Lung Cancer
Post-ET Myelofibrosis
Post-PV MF
Primary Myelofibrosis
Phase 1
Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer
Withdrawn
NCT05705466
Kartos Therapeutics, Inc.
Non Small Cell Lung Cancer
Start: 2023-06-30
End: 2027-06-30
Updated: 2024-03-22
Phase 2
Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
Recruiting
NCT05797831
Kartos Therapeutics, Inc.
Endometrial Cancer
Start: 2023-07-17
End: 2027-07-31
Target: 268
Updated: 2024-05-02
Phase 3
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Recruiting
NCT06479135
Kartos Therapeutics, Inc.
MF, Myelofibrosis, Post-ET Myelofibrosis +2
Start: 2024-06-03
End: 2028-12-31
Target: 600
Updated: 2025-09-25
Related Papers
POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib.
2026-03-07
Results from the Randomized, Multicenter, Global Phase 3 BOREAS Study: Navtemadlin Versus Best Available Therapy in JAK Inhibitor Relapsed<i>/</i>Refractory Myelofibrosis
Blood
2024-11-05
8 citations
Disease-Modifying Activity of Navtemadlin Correlates with Clinical Responses in a Randomized, Multicenter, Global Phase 3 Study (BOREAS) in JAK-Inhibitor Relapsed/Refractory Myelofibrosis
Blood
2024-11-05
5 citations
POIESIS: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Phase 3 Study of Navtemadlin As Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Blood
2024-11-05
3 citations
TP008/#1500 Trial in progress: phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer who responded to chemotherapy (ENGOT-EN21; GOG-3089)
2023-11-01
#84 Trial in progress: a phase 2/3 study of navtemadlin as maintenance therapy in patients with advanced or recurrent endometrial cancer (EC) who responded to chemotherapy (ENGOT-En21 and GOG-3089)
2023-09-01